The prostate cancer R&D pipeline is showing a swing toward innovative therapies and away from the current standard of hormonal treatments where there is limited scope for increases in efficacy. If these new therapies are able to penetrate the market, it could soon be one of the most active areas of cancer therapy research. Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond provides an in-depth analysis of the prostate cancer pipeline, and a competitive analysis of the most promising classes and drugs in development. The report enables you to competitively position your products, strengthen your marketing strategy and market penetration, expose potential threats to your business and target R&D resources more effectively.
